BR112012011678A2 - composição e métodos para afetar a produção de citocinas e nf-kb - Google Patents

composição e métodos para afetar a produção de citocinas e nf-kb

Info

Publication number
BR112012011678A2
BR112012011678A2 BR112012011678A BR112012011678A BR112012011678A2 BR 112012011678 A2 BR112012011678 A2 BR 112012011678A2 BR 112012011678 A BR112012011678 A BR 112012011678A BR 112012011678 A BR112012011678 A BR 112012011678A BR 112012011678 A2 BR112012011678 A2 BR 112012011678A2
Authority
BR
Brazil
Prior art keywords
composition
production
various
methods
affecting
Prior art date
Application number
BR112012011678A
Other languages
English (en)
Inventor
Dahl Andrew
Callewaert Dennis
Martinez Enrique
Sarkar Fazlul
Thomas Tiffany
Original Assignee
Health Enhancement Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Enhancement Products Inc filed Critical Health Enhancement Products Inc
Publication of BR112012011678A2 publication Critical patent/BR112012011678A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição e método para afetar a produção de citocinas e nf-kb. a presente invenção descreve uma composição e método para afetar a produção de várias citocinas e nf-b pela administração de uma quantidadde eficaz de uma composição de fito-percolado a um indivíduo. em várias modalidades exemplificadas, a composição é reivindicada como sendo útil para o tratamento eficaz de inflamação, câncer, e/ou várias infecções incluindo hiv pela regulação de várias interleucinas, tal como il-10 e il-2, e de fatores de transcrição incluindo nf-b.
BR112012011678A 2009-11-16 2010-11-16 composição e métodos para afetar a produção de citocinas e nf-kb BR112012011678A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26163909P 2009-11-16 2009-11-16
PCT/US2010/056862 WO2011060427A2 (en) 2009-11-16 2010-11-16 Composition and methods for affecting cytokines and nf-kb

Publications (1)

Publication Number Publication Date
BR112012011678A2 true BR112012011678A2 (pt) 2018-04-17

Family

ID=43992472

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011678A BR112012011678A2 (pt) 2009-11-16 2010-11-16 composição e métodos para afetar a produção de citocinas e nf-kb

Country Status (6)

Country Link
US (1) US20110117122A1 (pt)
EP (1) EP2501390A4 (pt)
JP (1) JP2013510905A (pt)
BR (1) BR112012011678A2 (pt)
CA (1) CA2780144A1 (pt)
WO (1) WO2011060427A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166270B2 (en) 2004-04-23 2019-01-01 Zivo Bioscience, Inc. Composition and method for affecting cytokines and NF-κB
CA2827401A1 (en) 2010-02-22 2011-08-25 Health Enhancement Products, Inc. Agents and mechanisms for treating hypercholesterolemia
WO2014201372A1 (en) 2013-06-13 2014-12-18 Health Enhancement Products, Inc. Compounds and methods for affecting cytokines
WO2016133922A1 (en) 2015-02-16 2016-08-25 Zivo Bioscience, Inc. Methods of modulating immune and inflammatory responses via administration of an algal biomass
CN109414053A (zh) 2016-02-16 2019-03-01 齐沃生物科学股份有限公司 经由给予源自藻类的补充物的动物营养支持

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15587A (en) * 1856-08-19 Aepabattts for boeing artesian wells
US10480A (en) * 1854-01-31 Improvement in electro-magnettc engines
US9479A (en) * 1852-12-21 Improvement in rakes to grain-harvesters
JPS6219528A (ja) * 1985-07-16 1987-01-28 Kurorera Kogyo Kk 制癌剤
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
DE60012026T2 (de) * 1999-08-26 2004-12-30 Ganeden Biotech, Inc., San Diego Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien
WO2001022834A2 (en) * 1999-09-27 2001-04-05 Algal Ltd. Vegetarian foodstuff
ATE265218T1 (de) * 2000-08-10 2004-05-15 Ocean Nutrition Canada Ltd Chlorella zubereitungen mit immunmodulatorischen eigenschaften
EP1409000A4 (en) * 2000-08-18 2004-04-21 Atlas World Usa Inc USE OF AGARICUS BLAZEI MURILL FOR THE PREPARATION AND TREATMENT OF SKIN AND OTHER DISEASES
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
AU2003287622A1 (en) * 2002-11-06 2004-06-03 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US20130251698A1 (en) * 2010-10-04 2013-09-26 Health Enhancement Products, Inc. Composition and method for affecting cytokines and nf-kb
US7807622B2 (en) * 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US20080031863A1 (en) * 2004-04-23 2008-02-07 Health Enhancement Products, Inc. Method of Preparation and Use of Fibrinolytic Enzymes in the Treatment of Disease
WO2007065024A2 (en) * 2005-12-02 2007-06-07 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US8586053B2 (en) * 2005-09-21 2013-11-19 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease

Also Published As

Publication number Publication date
US20110117122A1 (en) 2011-05-19
EP2501390A4 (en) 2014-07-02
JP2013510905A (ja) 2013-03-28
WO2011060427A9 (en) 2011-09-15
EP2501390A2 (en) 2012-09-26
CA2780144A1 (en) 2011-05-19
WO2011060427A2 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
PH12020500352A1 (en) Therapeutic uses of empagliflozin
NI201200030A (es) Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas.
MX2016001023A (es) Formulaciones que contienen dapagliflozina amorfa.
NZ749217A (en) Androgen receptor modulator and uses thereof
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
MX2012009718A (es) Material biodegradable que contiene silicio para terapia antiinflamatoria.
MX2020013740A (es) Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
EP2750694B8 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
MX365650B (es) Composiciones de amantadina y metodos para su uso.
BR112012018170B8 (pt) agente antimicrobiano para redução, inibição ou tratamento do crescimento microbiano, infecções microbianas, doenças inflamatórias, doenças ou condições virais resultantes de ou associadas aos mesmos
BR112012011678A2 (pt) composição e métodos para afetar a produção de citocinas e nf-kb
UY32444A (es) Composiciones y procedimientos para terapia extendida con aminopiridinas
MX2014000515A (es) Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido.
CL2012002902A1 (es) Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas.
MX354383B (es) Sistemas, métodos y formulaciones para tratamiento de cáncer.
MX341300B (es) Composiciones para el tratamiento de ulceras perifericas de varios origenes.
GB2525517A (en) Topical preparation for pain relief
CO7240352A2 (es) Profármacos novedosos de rebampida, método de preparación y uso del mismo
MX2013011694A (es) Analogos de taxano y abeo-taxanos.
MX354667B (es) Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas.
NZ711238A (en) Compositions and methods for treating multi-drug resistant malaria
MX347245B (es) Composiciones para el tratamiento de úlceras periféricas de diversos orígenes.
JO3688B1 (ar) مركب صيدلاني على شكل معلق فمي يضم جزء فلافونويد وصمغ الكزانتان
BR112014028632A8 (pt) Composto, composição farmacêutica, e, método para preparar um composto
BR112012020934A8 (pt) Processo para purificação da alfa-manosidase lisossomal humana recombinante a partir de uma cultura celular, composição, processo em batelada alimentada ou produção contínua da alfa-manosidase lisossomal humana recombinante e uso da composição

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ZIVO BIOSCIENCE, INC. (US)

B25G Requested change of headquarter approved

Owner name: ZIVO BIOSCIENCE, INC. (US)

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal: appeal against refusal